Keyword Analysis & Research: amiloride for diabetes insipidus

clinicaltrials.gov

https://clinicaltrials.gov/ct2/show/NCT05044611

Sep 16, 2021 · AMIloride for the Treatment of Nephrogenic Diabetes Insipidus for Patients With Bipolar Disorder Treated With Lithium (AMIND) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Allocation: Randomized Intervention Model: Single Group Assignment Estimated Enrollment : 148 participants Study Type : Interventional (Clinical Trial)

Allocation: Randomized

Intervention Model: Single Group Assignment

Estimated Enrollment : 148 participants

Study Type : Interventional (Clinical Trial)

DA: 50 PA: 62 MOZ Rank: 38

nih.gov

https://pubmed.ncbi.nlm.nih.gov/19367330/

Amiloride blocks lithium entry through the sodium channel thereby attenuating the resultant nephrogenic diabetes insipidus. Lithium therapy frequently induces nephrogenic diabetes insipidus; amiloride appears to prevent its occurrence in some clinical cases. Amiloride blocks the epithelial sodium channel (ENaC) located in the apical membrane of principal cells; hence … Publish Year: 2009 Author: Marleen L.A. Kortenoeven, Yuedan Li, Stephen Shaw, Hans-Peter Gaeggeler, Bernard C. Rossier, Jack F....

Publish Year: 2009

Author: Marleen L.A. Kortenoeven, Yuedan Li, Stephen Shaw, Hans-Peter Gaeggeler, Bernard C. Rossier, Jack F....

DA: 36 PA: 14 MOZ Rank: 52

diabetestalk.net

https://diabetestalk.net/diabetes/how-does-amiloride-treat-diabetes-insipidus

Apr 08, 2018 · Lithium therapy frequently induces nephrogenic diabetes insipidus; amiloride appears to prevent its occurrence in some clinical cases. Amiloride blocks the epithelial sodium channel (ENaC) located in the apical membrane of principal cells; hence one possibility is that ENaC is the main entry site for lithium and the beneficial effect of amiloride may be through …

DA: 6 PA: 61 MOZ Rank: 35

nih.gov

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1717946/

Hydrochlorothiazide-amiloride in the treatment of congenital nephrogenic diabetes insipidus. Am J Nephrol. 1985;5(1):9–13. [PubMed] [Google Scholar] Uyeki TM, Barry FL, Rosenthal SM, Mathias RS. Successful treatment with hydrochlorothiazide and amiloride in an infant with congenital nephrogenic diabetes insipidus. Pediatr Nephrol. Publish Year: 1999 Author: Veronika Kirchlechner, Dieter Y Koller, Reiner Seidl, Franz Waldhauser

Publish Year: 1999

Author: Veronika Kirchlechner, Dieter Y Koller, Reiner Seidl, Franz Waldhauser

DA: 60 PA: 39 MOZ Rank: 33

nih.gov

https://www.niddk.nih.gov/health-information/kidney-disease/diabetes-insipidus

The main complication of diabetes insipidus is dehydration if fluid loss is greater than liquid intake. Signs of dehydration include Severe dehydration can lead to seizures, permanent brain damage, and even death. Usually, people can prevent dehydration by increasing the amount of liquids they drink.

DA: 56 PA: 32 MOZ Rank: 92

medicalnewstoday.com

https://www.medicalnewstoday.com/articles/183251.php

Diabetes insipidus is a condition where the body loses too much fluid through urination, causing a significant risk of dangerous dehydration as well as a range of other illnesses and conditions. It is a rare disorder affecting the regulation of body fluid levels.

DA: 56 PA: 7 MOZ Rank: 80

medicalnewstoday.com

http://www.medicalnewstoday.com/articles/183251.php

The disease takes two main forms: Mephrogenic diabetes insipidus and central or neurogenic diabetes insipidus. Central diabetes insipidus occurs when the pituitary gland fails to secrete the hormone vasopressin, which regulates bodily fluids.

DA: 53 PA: 3 MOZ Rank: 97